Methods in Education for Breast Cancer Genetics
2 other identifiers
interventional
170
1 country
1
Brief Summary
In 1997, the Genetics Department of the NCI Medicine Branch helped establish a breast cancer genetics program at the National Naval Medical Center s Breast Care Center. Genetic education, counseling, and germline testing for BRCA1 and BRCA2, two genes which confer increased lifetime risks for breast and ovarian cancer, were offered under a Navy IRB-approved study. Sixty participants received education and counseling on that protocol, 49 of whom chose to have genetic testing. The education and counseling, provided by oncology nurses trained in cancer genetics, focused on preparing participants to make well-informed decisions about testing. Included were information on cancer and genetics; hereditary breast/ovarian cancer syndrome; risks, benefits and limitations of BRCA1/BRCA2 testing; and screening and risk reduction options for high-risk individuals. Through our experience with this study, we devised two different methods of providing this information. Both of these methods were well received and appear to be equally effective, as measured by knowledge assessments before and after the sessions and subjective evaluation by the participants. We will now study them in a randomized fashion in the current protocol, to better evaluate whether one method is preferable. Ultimately we hope to be able to make recommendations that will allow for access to genetic education and counseling for more individuals in a more cost efficient manner.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3 breast-cancer
Started Apr 1999
Longer than P75 for phase_3 breast-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 6, 1999
CompletedFirst Submitted
Initial submission to the registry
November 3, 1999
CompletedFirst Posted
Study publicly available on registry
November 4, 1999
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 6, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 6, 2017
CompletedDecember 12, 2019
December 6, 2017
18.7 years
November 3, 1999
December 11, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Impact of Events Scale
Baseline, 3, 6, and 12 months
Breast Cancer Genetics Knowledge Score
Baseline, 3, 6, and 12 months
Study Arms (2)
Group
EXPERIMENTALGroup education and counseling
Individual
ACTIVE COMPARATORIndividual education and counseling
Interventions
Eligibility Criteria
You may qualify if:
- At least one of the following:
- Diagnosis of breast cancer, or DCIS prior to or at 45, or ovarian cancer prior to or at age 50;
- Diagnosis of breast cancer with bilateral disease or multiple primaries or breast cancer and ovarian cancer in the same individual;
- Diagnosis of breast or ovarian cancer and one first or second degree relative with breast cancer diagnosed prior to or at age 45, or ovarian cancer prior to or at age 50;
- Diagnosis of breast or ovarian cancer and three relatives in the same lineage with breast or ovarian cancer; each affected individual must be a first- or second-degree relative to another of the affected individuals;
- Diagnosis of breast or ovarian cancer and a first or second degree male relative with breast cancer;
- A woman of Ashkenazi Jewish descent who meets any of the above criteria, with specified ages of onset of 50 for breast cancer and any age for ovarian cancer;
- A male with breast cancer diagnosed at any age;
- Documented BRCA mutation in the family.
- All individuals must be able to give informed consent.
You may not qualify if:
- Patients will be considered ineligible for any of the following reasons:
- Any psychological disorder which may hinder the participant's ability to understand and process the material, based on a psychiatric consultation.
- Inable to return for 2 visits.
- Age under 18 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Walter Reed National Medical Center
Bethesda, Maryland, 20301, United States
Related Publications (3)
Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996 May;14(5):1730-6; discussion 1737-40. doi: 10.1200/JCO.1996.14.5.1730.
PMID: 8622094BACKGROUNDStatement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet. 1994 Nov;55(5):i-iv. No abstract available.
PMID: 7977337BACKGROUNDHoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995 Feb 15;273(7):577-85.
PMID: 7837392BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kathleen Calzone, R.N.
National Cancer Institute (NCI)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 1999
First Posted
November 4, 1999
Study Start
April 6, 1999
Primary Completion
December 6, 2017
Study Completion
December 6, 2017
Last Updated
December 12, 2019
Record last verified: 2017-12-06